Overview

The Clinical Evaluation of the Dose of Erythropoietins Trial

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
0
Participant gender:
All
Summary
Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESAs) are the most used treatment option. The purpose of this study is 1. the evaluation of biochemical markers to determine the efficacy of individual prediction of ESAs therapy 2. to determine the benefits and harms of different ESA doses therapeutic strategy for the management of anaemia of end stage kidney disease (ESKD).
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Giovanni FM Strippoli, MD
Treatments:
Epoetin Alfa
Hematinics
Criteria
Inclusion Criteria:

- Age > = 18,

- End stage kidney disease and anemia

- Treatment with hemodialysis for renal replacement therapy

- no contraindications to erythropoietin stimulating agents (ESAs) or already treated
with ESAs

Exclusion Criteria:

- Patients with Hb levels > 10 g/dl without ESAs